Multi-omics Studies of Primary Aldosteronism

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-15

Study Completion Date

2029-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary aldosteronism is a prevalent yet underdiagnosed cause of secondary hypertension, contributing to significant cardiovascular morbidity and renal dysfunction. Despite affecting up to 20% of hypertensive patients, PA is frequently missed because it lacks distinctive clinical features and often presents with nonspecific symptoms like resistant hypertension or subtle electrolyte imbalances. The diagnostic pathway involves a stepwise approach: initial screening via the aldosterone-to-renin ratio, confirmatory testing (e.g., saline suppression or captopril challenge), and subtype differentiation using adrenal venous sampling to distinguish unilateral adenoma from bilateral hyperplasia. This complexity, combined with clinician unfamiliarity and variable access to specialized centers, perpetuates underdiagnosis. Early identification and tailored treatment are paramount in improving outcomes for patients with primary aldosteronism.

In this study, we will conduct a comprehensive multi-omics analysis on three sample types: 1) blood and urine samples from patients with primary aldosteronism, primary hypertension, and healthy controls; and 2) adrenal tissue samples from patients undergoing adrenalectomy for aldosterone-producing adenomas. We aim to systematically identify differentially expressed biomarkers that could serve as potential early diagnostic markers for primary aldosteronism. The findings may provide new insights into disease pathogenesis and contribute to improving early detection and personalized treatment strategies for this condition.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Plasma Metabolomics Profiling of Primary Aldosteronism

NCT06500000

Primary Aldosteronism Essential Hypertension Idiopathic Aldosteronism +1 more

COMPLETED

Diagnosing Variable Primary Aldosteronism.

NCT05765786

Primary Aldosteronism High Blood Pressure

RECRUITING

Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension

NCT05925569

Primary Aldosteronism Resistant Hypertension Secondary Hypertension +3 more

ACTIVE_NOT_RECRUITING NA

New Screening and Diagnostic Cut-off Points of PA Patients

NCT06571084

Primary Aldosteronism

RECRUITING

Spatial Proteomics Profiles of Aldosterone-producing Adenoma and Unilateral Hyperplasia

NCT05927961

Primary Aldosteronism Due to Aldosterone Producing Adenoma Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Aldosteronism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aldosterone-producing adenoma

Without intervention

Intervention Type OTHER

Without intervention

Idiopathic hyperaldosteronism

Without intervention

Intervention Type OTHER

Without intervention

Primary Hpertension

Without intervention

Intervention Type OTHER

Without intervention

Health control

Without intervention

Intervention Type OTHER

Without intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Without intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosed with primary aldosteronism , primary hypertension , or age- and sex-matched healthy controls;
2. Aged 18-80 years with complete medical records;
3. Willing to participate voluntarily and provide informed consent.

Exclusion Criteria

1. History of chemotherapy or radiotherapy in the adrenal region ;
2. Positive serological or nucleic acid test results for HIV, hepatitis B, or hepatitis C , or a prior confirmed diagnosis;
3. Individuals with malignancies or autoimmune disorders ;
4. Study withdrawal during the trial period

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes